Previous studies have shown that continuous subcutaneous insulin infusions can lead to improvements in clinical and quality of life benefits as compared to multiple daily injections of insulin. In this study, researchers led by Sanjeev Mehta, MD, MPH, of the Joslin Diabetes Center at Harvard University, test that concept in type 1 diabetes patients.
Study authors examined the risk of ED visits or hospitalizations for hypoglycemia among patients older than 65 who were initiated on glargine, detemir, or NPH insulin.
A history of severe hypoglycemia may be associated with alterations in cardiac function in older adults with type 2 diabetes.
The FDA has approved the first generic equivalent of Glucagon Emergency Kit (Lilly), according to Amphastar Pharmaceuticals.
A recent Morbidity and Mortality Weekly Report (MMWR) highlights the risks associated with use of over-the-counter (OTC) products containing undeclared prescription ingredients as well as the importance of collaboration between various health departments and systems to ensure a prompt response to an outbreak.
Researchers developed a clinical tool to identify patients at risk for persistent abnormal glucose levels during hospitalization.
Golimumab was found to preserve β-cell function and reduce the need for exogenous insulin in young patients with type 1 diabetes.
The FDA has accepted for review the New Drug Application for dasiglucagon HypoPal® Rescue Pen (Zealand Pharma) for the treatment of severe hypoglycemia.
Several nonglycemic factors may increase the risk for the development of diabetic peripheral neuropathy (DPN) among people with type 1 diabetes.
The FDA has granted Orphan Drug designation to ABG-023, a glucagon analog (AmideBio), for the treatment of congenital hyperinsulinism.
